Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3

REFERENCES

• Soriano V, Barreiro P, Nunez M. Management of chronic hepatitis B and C in HIV-coinfected patients. J Antimicrob Chemother 2006;57:815–818.
   Google Scholar
• Thio CL. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treat-ment. Semin Liver Dis. 2003;23:125–136.
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis. 2005;192:992–1002.
   PubMed Web of Science ®Google Scholar
• Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J HepatoL 2006;44:S6–S9.
   PubMed Web of Science ®Google Scholar
• Puoti M, Airoldi M, Bruno R, et al. Hepatitis B virus co-infection in human immunodeficiency virus-infected sub-jects. AIDS Rev. 2002;4:27–35.
   PubMedGoogle Scholar
• Poles MA, Dieterich DT. Hepatitis C virus/human immuno-deficiency virus coinfection: clinical management issues. Clin Infect Dis. 2000;31:154–161.
   PubMed Web of Science ®Google Scholar
• den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hep-atitis B and C virus co-infection and the risk for hepatotox-icity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000;14: 2895–2902.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hep-atotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74–80.
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Mats V, Walczak D. Systemic overview of HAART-associated liver enzyme elevations in patients infected with HIV and coinfected with HCV. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5–8, 2006; Denver, Colorado, USA. Abstract 88.
   Google Scholar
• Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without con-current ritonavir. AIDS. 2004;18:2277–2284.
   Google Scholar
• Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis. 2004;38: S80–S89.
   PubMed Web of Science ®Google Scholar
• Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepa-totoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005;191:825–829.
   PubMed Web of Science ®Google Scholar
• Law WP, Dore GJ, Duncombe CJ, et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS. 2003;17:2191–2199.
   PubMed Web of Science ®Google Scholar
• Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS. 200115: 1261–1268.
   Google Scholar
• Katlama C, Esposito R, Gate JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 2007;21: 395–402.
   PubMed Web of Science ®Google Scholar
• Haubrich R, Berger D, Chiliade P, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS. 2007;21:F11—F18.
   PubMed Web of Science ®Google Scholar
• Molina J, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treat-ment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr 2007. [Epub ahead of print]
   Web of Science ®Google Scholar
• Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169–1178.
   PubMed Web of Science ®Google Scholar
• Sekar V, De Meyer S, Vangeneugden T, et al. Pharmaco-kinetic/pharmacodynamic (PK/PD) analyses of TMC114 in the POWER 1 and POWER 2 trials in treatment-expe-rienced HIV-infected patients. Presented at: 13th Con-ference on Retroviruses and Opportunistic Infections; February 5–8, 2006; Denver, Colorado, USA. Abstract J–121.
   Google Scholar
• D'Aquila RT, Schapiro JM, Brun-Vezinet F, et al. Drug resis-tance mutations in HIV-1. Top HIV Med. 2003;11:92–96.
   PubMedGoogle Scholar
• Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2005. Top HIV Med. 2005;13:51–57.
   PubMedGoogle Scholar
• AIDS Clinical Trials Group. Division of AIDS table for grad-ing severity of adult adverse experiences—August 1992. Available at: http://rcc.tech-res.com/DAIDS%2ORCC%20Forms/ToxicityTables_Adult_TRP_v01a.pdf. Accessed September 12, 2006.
   Google Scholar
• Medical Dictionary for Regulatory Activities Terminology (MedDRA), with expanded abbreviations, Version 6.1, September, 2003. International Conference on Harmo-nization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Available at: http://meddramsso.com. Accessed September 12, 2006.
   Google Scholar
• Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002;35: 182–189.
   PubMed Web of Science ®Google Scholar
• Servin-Abad L, Molina E, Baracco G, et al. Liver enzymes elevation after HAART in HIV-HCV co-infection. J Viral Hepat. 2005;12: 429–434.
   PubMed Web of Science ®Google Scholar
• Torti C, Lapadula G, Uccelli MC, et al. Influence of viral chronic hepatitis co-infection on plasma drug concen-trations and liver transaminase elevations upon therapy switch in HIV-positive patients. Int J Antimicrob Agents. 2007;29:185–190.
   PubMed Web of Science ®Google Scholar